Fulvestrant — Drug Intelligence | 62 EU Trials

Filter these 62 trials by condition, phase, country and more.

Open in Search →

62 Registered trials

26 Recruiting

34 Completed trials

37 Sponsors

21 Countries

Phase III

Phase II

Phase III: 23 Phase II/III: 2 Phase II: 23 Phase I/II: 3 Phase III/IV: 1 Phase IV: 4 Phase I (Other): 1 Phase I (FiH): 5

Oversight events:

9 temporary halts 3 urgent safety measures 1 unexpected event 1 corrective measure across 7 trials

View oversight register →

Indications tested

Hormone receptor positive HER2 negative breast cancer 10 Breast cancer 6 Breast cancer metastatic 6 Hormone receptor positive breast cancer 4 Breast cancer female 3 Ovarian cancer 2 Hormone refractory breast cancer 1 Non-small cell lung cancer 1 Ovarian epithelial cancer 1 Triple positive breast cancer 1 Colorectal cancer metastatic 1 Neoplasm malignant 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 6 Pfizer Inc. 6 Unicancer 6 AstraZeneca AB 5 Novartis Pharma AG 4 Eli Lilly & Co. 3 Medica Scientia Innovation Research S.L. 3 Alliance Foundation Trials LLC 1 Blueprint Medicines Corp. 1 BOOG Study Center B.V. 1 Carrick Therapeutics Limited 1 Celcuity Inc. 1

All trials — page 3

62 total

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 Phase III 1 country Unicancer
A Study of abemaciclib Combined with Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Ended

2023-506781-30-00 Phase III 5 countries Eli Lilly & Co.
(VELA) Study of BLU-222 in Advanced Solid Tumors Ended

2022-502528-29-00 Phase I (FiH) 4 countries Blueprint Medicines Corp.
Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) me… Ended

2022-502372-22-01 Phase II 1 country Unicancer
Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients (DEMETER) Ended

2022-502360-21-00 Phase II 1 country Institut Curie
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced HR Positive and HER2-Negative BC Ended

2023-503903-27-00 Phase II 2 countries Carrick Therapeutics Limited
DESTINY-Breast08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other thera… Ended

2023-505690-33-00 Phase I (Other) 1 country Astrazeneca AB
Tucatinib and trastuzumab in solid tumors with HER2 alterations Ended

2024-511481-37-00 Phase II 3 countries Seagen Inc.
A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended

2023-509591-42-00 Phase II 3 countries Medica Scientia Innovation Research S.L.
Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients… Ended

2024-511295-33-00 Phase II 1 country Medica Scientia Innovation Research S.L.
Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Ended

2023-508135-30-00 Phase II 1 country Jazz Pharmaceuticals Ireland Limited
Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3C… Ended

2023-509167-24-00 Phase II 2 countries Novartis Pharma AG
Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg… Ended

2024-516132-10-00 Phase II 2 countries Fundacion Grupo Espanol De Investigacion En Cancer De Mama
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… Ended

2023-506487-13-00 Phase III 14 countries Pfizer Inc.

Showing 49–62 of 62 trials

← All drugs A–Z